



## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SE	HIAL NUMBER	FILING DATE	FIRST NAME	D INVENTOR		ATTORNEY DOCKET NO.
	08/026,736	03/05/93	) ALT70N	•		
	00/020, /30	03/03/93	3 ALIZON		<u>#</u>	3495.0010-12
	•					EXAMINER
			18M2/05(	0.4	FEISEE,	<u> </u>
	FINNEGAN, H	HENDERSON.	FARABOW, GARRE	J <del>y</del> ETT 9.	ART UNIT	PAPER NUMBER
	DUNNER		THE COLUMN	_ 1		112
	1300 I STRE	EET, N. W.				70
	WASHINGTON,	DC 20005-	3315		1806	
					DATE MAILED:	
Thie	is a communication fo	mm the average !-	alan da		-ATE HOUSELD.	05/04/94
COM	MISSIONER OF PAT	TENTS AND TRADE	charge of your application.			
					3/1	ماح ما
. /	1		A	,	'31'	דיוי
図	His application has be	benimaye nee	Responsive to communi		10/94 31	$\mathbf{k}$
		7	Tresponsive to continuin	cation filed on	<del></del>	This action is made final.
A sho	rtened statutory perio	od for response to thi	s action is set to expire	3 month(s).	(1) down from	and the state of the target
Failur	e to respond within th	ne period for respons	e will cause the application t	o become abandone	days no	m the date of this letter.
Part I					2. 00 0.0.0. 100	
Parti	THE PULLOWING	ATTACHMENT(S)	ARE PART OF THIS ACTIO	ON:		
1.	Motion of Dates					•
3.	Notice of Act Of	ences Cited by Exam	iner, PTO-892.	2. U Notice	of Draftsman's Pat	ent Drawing Review, PTO-948.
5.	Notice of Art Cr	ed by Applicant, PT	D-1449.	4.   Notice	of Informal Patent	Application, PTO-152.
	information on F	now to Effect Drawin	g Changes, PTO-1474.	6. ∐		
Part I	SUMMARY OF A	CTION		. •		i i
						· · · · · · · · · · · · · · · · · · ·
1/2	Ctaims	11.13.10	•			
	•			· · · · · · · · · · · · · · · · · · ·		are pending in the application.
- /	Of the above	, claims			are v	withdrawn from consideration.
1	<b>a</b>	1-10	12.14/6			
2./2	Claims		/ <u>~</u> //// Y			have been cancelled.
_ `C	Claims					
J. L	- Claims					are allowed.
4. 🔯	Claims	11 13	15			
<u>"</u> _		<del>- (                                   </del>	1-0	<del></del>		are rejected.
5. L	Claims					
_	•					are objected to.
6	Claims			are s	ubject to restriction	or election requirement.
- F	7					
/. ∟	ı ınıs application has	s been filed with Info	mal drawings under 37 C.F.	R. 1.85 which are acc	eptable for examin	ation purposes.
8. T	•		se to this Office action.			
9	The corrected or su	bstitute drawings ha	ve been received on		Linder 37 C F	D 1 04 those decide
	are acceptable;	not acceptable (s	ee explanation or Notice of I	Draftsman's Patent Dr	awing Review. PTO	R. 1.84 these drawings 0-948)
44 F						*
10	I The proposed addit	ional or substitute sh	neet(s) of drawings, filed on	, h	as (have) been 🛭	approved by the
	examiner; Li disap	proved by the exam	iner (see explanation).			
11.	The proposed drawing	na correction filed	<b>L</b>	. been [7	<b>-</b>	
			, has			
12	Acknowledgement is	made of the claim f	or priority under 35 U.S.C. 1	19. The certified con	vhas □heen re∽	eived not been received
	☐ been filed in pare	nt application, serial	no	filed on		One in the part received
اء ا						
. 3	accompance application	n apppears to be in o	condition for allowance excep	pt for formal matters,	prosecution as to th	e merits is closed in
	accordance with the	practice under Ex pa	arte Quayle, 1935 C.D. 11; 4	53 O.G. 213.		
🗂						

Serial Number: 08/026,736

Art Unit: 1806

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

All rejections and Objections are withdrawn except for the following:

Claims 11,13 and 15 remain rejected under 35 USC 101 as the claimed invention is inoperative and therefore lacks patentable utility for the same reasons as presented previously on pages 4-6 of paper #6.

Applicant argues that the claimed invention is useful for screening compositions for synthetic or natural peptides encoded by ORF-Q, ORF-R ORF-1, ORF-2 and ORF-4 of HIV-1. However as previously mentioned, the utility of these peptides has not been established. These ORFs have not been shown to be expressed in biological samples, and there is no practical utility associated with screening for peptides which do not occur in nature, especially with respect to HIV related peptides. It is maintained, that there is no beneficial function disclosed as being associated with the screening of synthetically produced peptides which are not normally expressed in nature.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION

Serial Number: 08/026,736

Art Unit: 1806

IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lila Feisee whose telephone number is (703) 308-2731.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Lila Feisee/lf May 2, 1994

PAULA K. HUTZELL PRIMARY EXAMINER GROUP 1800